Weight loss drugs have become the hottest selling drugs in the U.S. market this year, thanks in large part to Novo Nordisk’s products: Ozempic and Rybelsus, approved in 2018 and 2019 to treat type 2 diabetes, and Wegovy, which was approved in 2021 to treat obesity. The medications, which can lead to the largest weight loss yet seen with any prescription drug, are now in high demand, not just by patients who legitimately can benefit from them but also from those eager for a quick fix to drop a few extra pounds, despite the risks of nausea, vomiting and sometimes inflammation of the pancreas that the medications can cause.
Find out why Novo Nordisk was selected for the TIME100 Most Influential Companies list: ti.me/3NQtEqR
Subscribe to TIME’s KZfaq channel ►► ti.me/subscribe-time
Subscribe to TIME: ti.me/3H2FRoe
Get the day’s top headlines to your inbox, curated by TIME editors: ti.me/the-brief
Follow us:
Twitter: ti.me/40lqM8g
Facebook: ti.me/3UV11u9
Instagram: ti.me/3mU0Naj